SCIRP Mobile Website
Paper Submission

Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

 

Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
   
Paper Publishing WeChat
Book Publishing WeChat
(or Email:book@scirp.org)

Article citations

More>>

D. Von Au, M. Brandle, H. Rupp and R. Jacob, “Influence of Diet Rich in Fish Oil on Blood Pressure, Body Weight and Cardiac Hypertrophy in Spontaneously Hypertensive Rats,” European Journal of Applied Physiology and Occupational Physiology, Vol. 58, No. 1, January 1988, pp. 97-99.

has been cited by the following article:

  • TITLE: The Impact of Omega-3 Fatty Acid Use on the Risk of Atrial Fibrillation in Patients with Cardiovascular Disease

    AUTHORS: Brian J. Barnes, Patricia A. Howard, Scott Solomon, Warren Chen, James L. Vacek

    KEYWORDS: Omega-3 Fatty Acids, Atrial Fibrillation

    JOURNAL NAME: International Journal of Clinical Medicine, Vol.2 No.1, February 24, 2011

    ABSTRACT: Fish oils containing omega-3 fatty acids (OM3FA) are widely prescribed in the management of dyslipidemia. An asso-ciation between OM3FA and reduced risk of atrial fibrillation (AF) has been proposed. We examined the impact of OM3FA exposure on the risk of developing AF in patients with cardiovascular disease. Data was obtained from elec-tronic medical records of patients seen by our cardiology service between 2005 and 2007. Patients were excluded if AF developed prior to, or on the day of, OM3FA exposure. A total of 11,360 subjects were eligible for analyses. Subjects exposed to OM3FA were at higher risk for AF. Nearly all AF risk factors were significantly more prevalent in the OM3FA exposed group. As expected, those prescribed OM3FA were also more likely to be prescribed statins, ACE in-hibitors, aspirin, and beta blockers. AF occurred in 8.5% (221/2600) of OM3FA exposed subjects and 23.5% (2054/8760) of those not exposed. After controlling for AF risk factors, OM3FA exposed subjects were 74% less likely to develop AF than those not exposed to OM3FA (odds ratio 0.26, 95%CI 0.22-0.30, p